The “BASE” study, now published in The Lancet Rheumatology, found mortality, AESIs among SLE (Systemic Lupus Erythematosus) patients taking Benlysta similar to placebo.
Specifically, the study evaluated mortality and Adverse Events of Special Interest (AESIs) with intravenous Belimumab for adults with active, Autoantibody-positive Systemic lupus Erythematosus (BASE). This was a multicenter, double-blind, randomized, placebo-controlled, phase 4 trial with 4,000 participants in 33 countries.
You can read more about this study in The Lancet Rheumatology.